Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
Retrieved on:
Tuesday, October 10, 2023
College, Flagship Pioneering, Harbor, Therapy, Roivant Sciences, University, Novartis, Cancer, Memorial University of Newfoundland, AstraZeneca, MDNA, MIT, CMO, Harvard Medical School, Publication, College of American Pathologists, Science, Assistant, Scripps Research, Whitehead Institute, Glioblastoma, Translational medicine, Memorial University of Newfoundland Faculty of Medicine, Pharmaceutical industry, Biochemistry, Oncology, Biogen
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.
Key Points:
- TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.
- Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals,” said Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna.
- Previously, he was the CMO at Stingthera, CMO in Residence at Roivant Sciences and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company.
- Dr. Gardner holds a bachelor’s degree in Biochemistry and his medical degree from the University of Cambridge.